SiBone (NASDAQ:SIBN) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of SiBone (NASDAQ:SIBN) have been given a consensus rating of “Moderate Buy” by the seven ratings firms that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating and six have issued a buy rating on the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $24.6667.

SIBN has been the topic of a number of analyst reports. Wall Street Zen upgraded shares of SiBone from a “hold” rating to a “buy” rating in a research note on Saturday, March 28th. Weiss Ratings restated a “sell (d-)” rating on shares of SiBone in a research report on Monday, December 29th. Truist Financial reaffirmed a “buy” rating and set a $24.00 price target (up from $23.00) on shares of SiBone in a report on Tuesday, February 24th. Canaccord Genuity Group lifted their price objective on shares of SiBone from $26.00 to $27.00 and gave the company a “buy” rating in a research note on Wednesday, December 17th. Finally, TD Cowen boosted their price objective on shares of SiBone from $21.00 to $22.00 and gave the company a “buy” rating in a research report on Tuesday, February 24th.

Insider Buying and Selling

In other news, CEO Laura Francis sold 93,475 shares of the business’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $15.32, for a total transaction of $1,432,037.00. Following the completion of the transaction, the chief executive officer owned 544,369 shares of the company’s stock, valued at approximately $8,339,733.08. The trade was a 14.65% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Michael A. Pisetsky sold 20,756 shares of the firm’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $15.35, for a total value of $318,604.60. Following the completion of the sale, the senior vice president directly owned 285,974 shares in the company, valued at $4,389,700.90. This trade represents a 6.77% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 187,697 shares of company stock worth $2,976,686. 4.00% of the stock is owned by company insiders.

Institutional Investors Weigh In On SiBone

Several hedge funds and other institutional investors have recently made changes to their positions in SIBN. First Light Asset Management LLC lifted its stake in SiBone by 162.4% in the 4th quarter. First Light Asset Management LLC now owns 5,032,904 shares of the company’s stock valued at $99,249,000 after purchasing an additional 3,115,001 shares during the last quarter. American Century Companies Inc. grew its stake in shares of SiBone by 22.5% during the third quarter. American Century Companies Inc. now owns 2,838,107 shares of the company’s stock worth $41,777,000 after buying an additional 521,683 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of SiBone by 0.5% during the fourth quarter. Vanguard Group Inc. now owns 2,501,555 shares of the company’s stock worth $49,331,000 after buying an additional 11,566 shares during the last quarter. Nuveen LLC grew its stake in shares of SiBone by 5.1% during the fourth quarter. Nuveen LLC now owns 1,421,946 shares of the company’s stock worth $28,041,000 after buying an additional 69,229 shares during the last quarter. Finally, Impax Asset Management Group plc increased its holdings in shares of SiBone by 17.1% during the fourth quarter. Impax Asset Management Group plc now owns 1,200,010 shares of the company’s stock worth $23,664,000 after buying an additional 175,000 shares in the last quarter. 98.11% of the stock is owned by institutional investors.

SiBone Stock Performance

Shares of SIBN stock opened at $13.12 on Monday. The stock has a market cap of $579.51 million, a P/E ratio of -29.82 and a beta of 0.77. SiBone has a 1 year low of $12.15 and a 1 year high of $21.89. The company has a current ratio of 8.55, a quick ratio of 7.21 and a debt-to-equity ratio of 0.20. The stock has a 50 day simple moving average of $14.62 and a 200 day simple moving average of $16.39.

SiBone (NASDAQ:SIBN) last posted its quarterly earnings data on Monday, February 23rd. The company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.09. SiBone had a negative return on equity of 11.01% and a negative net margin of 9.41%.The firm had revenue of $56.35 million for the quarter, compared to analyst estimates of $56.26 million. On average, research analysts predict that SiBone will post -0.78 earnings per share for the current fiscal year.

SiBone Company Profile

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.